Relay Therapeutics, Inc. (RLAY)

6,36 -0,06 (-0,93%) Al cierre: 04:00PM EDT

Relay Therapeutics, Inc.

399 Binney Street
2nd Floor
Cambridge, MA 02139
United States
617 370 8837
https://www.relaytx.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 309

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Alexis A. Borisy A.M.	Co-Founder & Independent Chairman	92,5k	N/A	1972
Dr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBS	CEO, President & Director	1,08M	1,96M	1974
Dr. Mark Murcko Ph.D.	Co-Founder & Director	60k	N/A	1960
Mr. Thomas Catinazzo	Chief Financial Officer	663,99k	N/A	1977
Mr. Brian R. Adams J.D.	Chief Legal Officer & Secretary	627,72k	N/A	1974
Mr. Peter Rahmer	Chief Corporate Development Officer	626,62k	N/A	N/A
Dr. Donald A. Bergstrom M.D., Ph.D.	President of Research & Development	1,37M	N/A	1972
Mr. Jim Watters Ph.D.	Chief Scientific Officer of Late Research	N/A	N/A	N/A
Dr. Beni B. Wolf M.D., Ph.D.	Chief Medical Officer & Head of Precision Medicine	N/A	N/A	N/A
Dr. Mahesh Padval Ph.D.	Chief Pharmaceutical Development Officer	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Gobierno corporativo

El ISS Governance QualityScore de Relay Therapeutics, Inc., a día 1 de mayo de 2024, es 7. Las puntuaciones base son Auditoría: 6; Tablero: 7; Derechos de los accionistas: 8; Compensación: 8.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.